search
Back to results

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

Primary Purpose

Crohn's Disease

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
budesonide
mesalazine
Sponsored by
Dr. Falk Pharma GmbH
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Crohn's Disease

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria (main): Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes] Localisation of CD either in terminal ileum, ascending colon or ileocolitis Active phase of disease (200 < CDAI < 400) Exclusion Criteria (main): Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms CD in the rectum currently present Short bowel syndrome Septic complications Baseline stool positive for germs causing bowel disease Abscess, perforation or active fistulas Ileostomy or colostomy Resection of more than 50 cm of the ileum Bowel surgery within the last 3 months Immediate surgery required Clinical signs of stricturing disease Subileus within the last 6 months Suspicion of ileus, subileus or corresponding symptomatology Contra-indications, special warnings and precautions mentioned in SmPC Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit Treatment with anti-TNF-a therapy within 6 months before baseline visit Conventional steroids (iv, po, rectal) within 2 weeks before the study > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study Patients known to be steroid-refractory or steroid-dependent from former CD episodes Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks

Sites / Locations

  • Ev. Krankenhaus Hattingen GmbH

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

A

B

Arm Description

Outcomes

Primary Outcome Measures

Rate of remission

Secondary Outcome Measures

Response to treatment
Time to response
Time to remission
PGA
QoL

Full Information

First Posted
March 7, 2006
Last Updated
May 16, 2014
Sponsor
Dr. Falk Pharma GmbH
search

1. Study Identification

Unique Protocol Identification Number
NCT00300118
Brief Title
Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)
Official Title
Double-blind, Double-dummy, Randomized, Multicentre Study to Compare the Efficacy and Safety of Oral Budesonide (9 mg) and Oral Mesalazine (4.5 g) in Moderately Active Crohn's Disease Patients
Study Type
Interventional

2. Study Status

Record Verification Date
May 2014
Overall Recruitment Status
Completed
Study Start Date
September 2004 (undefined)
Primary Completion Date
May 2008 (Actual)
Study Completion Date
May 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Dr. Falk Pharma GmbH

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether mesalazine or budesonide is more active in the treatment of active Crohn's disease.
Detailed Description
Crohn's disease is often treated with glucocorticoids or mesalazine. Both drugs are indicated for active Crohn's disease. Treatment with mesalazine is indicated for the treatment of mildly to moderately active Crohn's disease. Budesonide 9 mg/day or mesalazine 4.5 g/day are better than lower doses. So far only one trial compares the efficacy and safety of budesonide and 5-ASA. The result of this trial is that budesonide is more effective in inducing remission than mesalazine. The primary objective of this trial is to confirm this result for other presentations of budesonide and mesalazine; i.e. Budenofalk® capsules (9 mg/day) and Salofalk® tablets (Eudragit-L-coated oral mesalazine; 4.5 g/day) in moderately active Crohn's disease. Mesalazine is used in this trial as a comparator.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Crohn's Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
311 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Title
B
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
budesonide
Intervention Description
9 mg
Intervention Type
Drug
Intervention Name(s)
mesalazine
Intervention Description
4.5 g
Primary Outcome Measure Information:
Title
Rate of remission
Secondary Outcome Measure Information:
Title
Response to treatment
Title
Time to response
Title
Time to remission
Title
PGA
Title
QoL

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria (main): Symptoms of Crohn's disease since at least 3 months; diagnosis confirmed by endoscopic and histological, or endoscopic and radiological criteria [endoscopy not older than 12 months or if older, then clinical signs (e.g. pain localization, pain intensity, blood in stool) and behaviour (according to Vienna classification) should be unchanged compared to former episodes] Localisation of CD either in terminal ileum, ascending colon or ileocolitis Active phase of disease (200 < CDAI < 400) Exclusion Criteria (main): Known Crohn's lesion in the upper GI-tract (up to and including the jejunum) with present symptoms CD in the rectum currently present Short bowel syndrome Septic complications Baseline stool positive for germs causing bowel disease Abscess, perforation or active fistulas Ileostomy or colostomy Resection of more than 50 cm of the ileum Bowel surgery within the last 3 months Immediate surgery required Clinical signs of stricturing disease Subileus within the last 6 months Suspicion of ileus, subileus or corresponding symptomatology Contra-indications, special warnings and precautions mentioned in SmPC Treatment with immunosuppressants, cytostatics, 6-TG, methotrexate, or cyclosporine within the last 3 months; in case of treatment with azathioprine or 6-MP the drugs have to be used for maintenance of remission only and dosage has to be unchanged within the last 3 months before baseline visit and during the study Treatment with ketoconazole, ciprofloxacin or other CYP3A inhibitors within the last month before baseline visit Treatment with anti-TNF-a therapy within 6 months before baseline visit Conventional steroids (iv, po, rectal) within 2 weeks before the study > 6 mg/d budesonide po or > 3 g/d mesalazine po within 2 weeks before the study Patients known to be steroid-refractory or steroid-dependent from former CD episodes Treatment of study disease with oral antibiotics (e.g., metronidazole) within the last 2 weeks
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andreas Tromm, Professor
Organizational Affiliation
Ev. Krankenhaus Hattingen GmbH
Official's Role
Principal Investigator
Facility Information:
Facility Name
Ev. Krankenhaus Hattingen GmbH
City
Hattingen
ZIP/Postal Code
45525
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
21070781
Citation
Tromm A, Bunganic I, Tomsova E, Tulassay Z, Lukas M, Kykal J, Batovsky M, Fixa B, Gabalec L, Safadi R, Kramm HJ, Altorjay I, Lohr H, Koutroubakis I, Bar-Meir S, Stimac D, Schaffeler E, Glasmacher C, Dilger K, Mohrbacher R, Greinwald R; International Budenofalk Study Group. Budesonide 9 mg is at least as effective as mesalamine 4.5 g in patients with mildly to moderately active Crohn's disease. Gastroenterology. 2011 Feb;140(2):425-434.e1; quiz e13-4. doi: 10.1053/j.gastro.2010.11.004. Epub 2010 Nov 9.
Results Reference
result

Learn more about this trial

Oral Budesonide vs. Oral Mesalazine in Active Crohn's Disease (CD)

We'll reach out to this number within 24 hrs